Novonesis
Novonesis is a Danish biosolutions company formed in 2024 through the merger of Novozymes and Chr. Hansen.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Novonesis is a Denmark-based biosolutions company created by the combination of Novozymes and Chr. Hansen. Its business is rooted in industrial biotechnology: using enzymes, microorganisms, fermentation, and related biological technologies to make products and processes more efficient, lower-resource, and potentially less dependent on conventional chemicals or fossil-based inputs. The company operates across applications that include food and beverages, agriculture, household care, bioenergy, and other industrial markets. The enterprise traces much of its scientific and commercial heritage to two Danish insulin companies founded in 1925 by brothers Harald and Thorvald Pedersen: Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium. That heritage later produced capabilities in fermentation and biological production. A predecessor introduced trypsin in 1941, using an animal-derived enzyme in leather processing, and developed enzyme production by bacterial fermentation during the 1950s. These developments helped establish the technical foundation for the enzyme business that eventually became Novozymes. Novozymes itself was established in 2000 as a spinout from Novo Nordisk. Before its combination with Chr. Hansen, it developed and manufactured industrial enzymes, microorganisms, and selected biopharmaceutical ingredients. Its best-known historical areas included enzymes for detergents, food processing, agriculture, bioenergy, and industrial manufacturing. In the late 1980s, the company presented Lipolase, described in the supplied reference material as the first fat-splitting detergent enzyme manufactured with genetically engineered microorganisms. During the 2000s, Novozymes expanded beyond its core enzyme activities through acquisitions in agricultural biologicals and related life-science fields. The company also reshaped its portfolio through divestments and targeted acquisitions. It spun out its biopharmaceutical operations into Albumedix in 2016, then announced acquisitions of PrecisionBiotics in 2020 and Microbiome Labs later that year. These transactions strengthened its presence in microbiome-related products and biological solutions while illustrating a broader strategy of using biotechnology platforms across multiple end markets. Novonesis was announced as the name of the combined Novozymes and Chr. Hansen company in December 2023 after the proposed merger received regulatory approval. The transaction was finalized on 29 January 2024 following final approval from the Danish Business Authority. The resulting company brings together Novozymes' enzyme and microbial technology base with Chr. Hansen's activities in cultures, enzymes, and microbial solutions for food, health, and agriculture. Novonesis presents this combination as a platform for developing biological alternatives and improving resource efficiency across industries. The company inherited an international operating footprint from Novozymes and Chr. Hansen, including activities in Europe, North America, Latin America, Asia, and other markets. Before the merger, Novozymes had operations in China, India, Brazil, Argentina, the United Kingdom, the United States, and Canada. The supplied sources do not provide a current consolidated revenue figure, share-price information, or a complete post-merger executive and ownership register. Novonesis should therefore be understood as the active successor brand and corporate entity, while Novozymes remains the relevant historical Wikipedia subject and predecessor company.
History
Novonesis is the successor to Novozymes, a Danish biotechnology company whose roots extend to the formation of Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium in 1925. Founded by brothers Harald and Thorvald Pedersen, the predecessor organizations initially focused on insulin production. Their fermentation and biological-production capabilities later supported the development of enzyme technologies. In 1941, a predecessor introduced trypsin, an enzyme extracted from animal pancreas and used in leather processing. During the 1950s, the organization became an early producer of enzymes through bacterial fermentation. This transition from extraction to microbial production was strategically important because fermentation could support more scalable and consistent biological manufacturing. Over subsequent decades, enzyme research expanded into detergents, food processing, agriculture, energy, and other industrial applications. In the late 1980s, Novozymes presented Lipolase, a fat-splitting enzyme for detergents produced with genetically engineered microorganisms. The product represented the company's role in replacing or reducing conventional chemical inputs in household-care formulations. Novozymes was established as an independent company in 2000 through a spinout from pharmaceutical company Novo Nordisk. As a standalone business, it focused on industrial enzymes, microorganisms, and selected biopharmaceutical ingredients. During the 2000s, Novozymes expanded through acquisitions, including businesses connected with agricultural biologicals and life sciences. The supplied reference material identifies Turfal in Brazil and EMD/Merck Crop BioScience in Germany among the acquired activities. These transactions broadened the company beyond its traditional enzyme base and helped establish a stronger position in biological approaches to agriculture. Novozymes subsequently adjusted its portfolio. In January 2016, it spun out its biopharmaceutical operations into Albumedix. In 2020, it announced plans to acquire PrecisionBiotics in Ireland and later announced the acquisition of Microbiome Labs. Both transactions reflected increasing interest in microbiome science and products based on beneficial microorganisms. The decisive corporate change came through the combination with Chr. Hansen, another Danish bioscience company. Regulatory approval for the merger was announced on 12 December 2023, and the name Novonesis was disclosed the next day. The transaction was completed on 29 January 2024 after final approval by the Danish Business Authority. Novonesis therefore combines Novozymes' long-established enzyme and fermentation expertise with Chr. Hansen's capabilities in cultures, enzymes, and microbial solutions serving food, health, agriculture, and related markets. Before the merger, Novozymes maintained operations in several major international markets, including China, India, Brazil, Argentina, the United Kingdom, the United States, and Canada. Its Class B shares were listed on the NASDAQ OMX Nordic exchange, while Novo Holdings held the Class A share capital and Novo A/S held a significant combined share of capital and voting rights. The supplied sources do not establish the complete current ownership, listing, leadership, or operating structure of Novonesis, so those details require further review.
- 2024
Merger completed
[1]The Novozymes and Chr. Hansen merger was finalized on 29 January 2024.
- 2023
Novonesis name announced
[1]The name Novonesis was revealed for the proposed combination of Novozymes and Chr. Hansen.
- 2016
Biopharmaceutical operations spun out
[1]Novozymes separated its biopharmaceutical operations into Albumedix.
- 2000
Novozymes established as a Novo Nordisk spinout
[1]The modern Novozymes company was formed as a standalone business after being spun out from Novo Nordisk.
- 1950
Bacterial fermentation used for enzyme production
[1]The predecessor organization became an early producer of enzymes through bacterial fermentation.
- 1941
First predecessor enzyme introduced
[1]A predecessor launched trypsin extracted from animal pancreas for use in leather processing.
- 1925
Founding of the predecessor insulin companies
[1]Harald and Thorvald Pedersen founded Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium, establishing the organizational and scientific heritage later associated with Novozymes and Novonesis.
Products and positioning
A science-led biosolutions provider using enzymes, microorganisms, fermentation, and related biotechnology to improve industrial, agricultural, food, health, and household-care processes while supporting more resource-efficient production.
Detergent enzyme
Lipolase
Lipolase was a fat-splitting enzyme for detergent applications. Introduced in the late 1980s, it was described in the supplied reference material as the first such detergent enzyme manufactured with genetically engineered microorganisms. It illustrates Novozymes' use of biotechnology to improve household-care formulations and reduce reliance on conventional chemical ingredients.
Industrial biotechnology · 1941
Industrial enzymes
Novozymes developed enzyme technologies for a wide range of industrial uses, including detergents, food processing, leather treatment, agriculture, bioenergy, and manufacturing. These products use biological catalysts to change production conditions, improve yields, or replace more resource-intensive chemical processes.
Agricultural biotechnology
Agricultural biologicals
The agricultural biologicals portfolio includes microbial and biological approaches intended to support crop production and agricultural efficiency. Novozymes expanded in this area through acquisitions during the 2000s, including activities associated with Turfal and EMD/Merck Crop BioScience.
Microbiome biotechnology · 2020
Microbiome solutions
Novozymes expanded into microbiome-related products and capabilities through the announced acquisitions of PrecisionBiotics and Microbiome Labs in 2020. The area uses beneficial microorganisms and microbiome science in applications connected with health and nutrition.
Food biotechnology · 2024
Food cultures and enzymes
Through the combination with Chr. Hansen, Novonesis includes cultures, enzymes, and microbial solutions for food and beverage production. These technologies can support fermentation, flavor, texture, preservation, and process consistency across food categories.
Brand decisions
2024
Merger with Chr. Hansen completedM&ABackground
Novozymes and Chr. Hansen pursued a combination to create a larger biosolutions company with complementary enzyme, culture, and microbial capabilities.
Action taken
The merger was finalized on 29 January 2024 after final regulatory approval, and the combined company operates as Novonesis.
Aftermath
Novonesis became the active successor brand and corporate platform, combining the two Danish bioscience businesses.
2020
Acquisition of PrecisionBiotics announcedM&ABackground
Novozymes sought to expand its presence in microbiome-related biotechnology.
Action taken
The company announced an agreement to acquire Ireland-based PrecisionBiotics.
Aftermath
The transaction added microbiome expertise to Novozymes' portfolio.
2020
Acquisition of Microbiome Labs announcedM&ABackground
Novozymes continued developing a microbiome-focused business area.
Action taken
The company announced the acquisition of Microbiome Labs.
Aftermath
The deal further broadened Novozymes' microbiome product and technology base.
2016
Spinout of biopharmaceutical operationsStrategyBackground
Novozymes separated its biopharmaceutical activities from the core enzyme and microorganism business.
Action taken
The operations were spun out into Albumedix.
Aftermath
The move narrowed Novozymes' direct operating scope while allowing the biopharmaceutical activities to continue separately.
Recent events
- 2024
Novozymes and Chr. Hansen merger finalized[1]
M&A · Other
The merger was completed on 29 January 2024 after final approval from the Danish Business Authority.
- 2023
Novozymes and Chr. Hansen receive approval for merger[1]
M&A · Other
The two Danish bioscience companies announced that they had obtained regulatory approval for their combination.
- 2023
Combined company is named Novonesis[1]
M&A · Leadership change
The proposed Novozymes–Chr. Hansen combination disclosed Novonesis as the name of the new company.
- 2020
Novozymes announces PrecisionBiotics acquisition[1]
M&A
Novozymes announced an agreement to acquire Ireland-based PrecisionBiotics, expanding its microbiome-related activities.
- 2020
Novozymes announces Microbiome Labs acquisition[1]
M&A
Novozymes announced a transaction to acquire Microbiome Labs and broaden its microbiome portfolio.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/novonesis · Editorial policy · How profiles are compiled